Literature DB >> 30911977

Childhood Vitiligo.

Electra Nicolaidou1, Styliani Mastraftsi2, Vassiliki Tzanetakou1, Dimitrios Rigopoulos1.   

Abstract

Vitiligo is a common acquired depigmenting skin disease characterized by a progressive loss of functional melanocytes. It may appear from the first years of life to late adulthood. Childhood vitiligo (CV), defined as vitiligo that begins before the age of 12 years, is common and may differ from post-CV in terms of epidemiology, clinical presentation, comorbidities, and treatment options. Taking into consideration the potential significant psychosocial impact of the disease on both children and their parents, all available therapeutic options must be offered to patients who desire treatment. According to the most recent guidelines, topical corticosteroids, topical calcineurin inhibitors, and narrowband ultraviolet B phototherapy are the most commonly used treatment modalities for vitiligo in children. This review presents recent data regarding the whole spectrum of CV. Differences between CV and post-CV are also discussed.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30911977     DOI: 10.1007/s40257-019-00430-0

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  3 in total

1.  Efficacy of the Topical Calcineurin Inhibitors Tacrolimus and Pimecrolimus in the Treatment of Vitiligo in Infants Under 2 Years of Age: A Randomized, Open-Label Pilot Study.

Authors:  Wenting Hu; Yongping Xu; Yangyang Ma; Jiehao Lei; Fuquan Lin; Ai-E Xu
Journal:  Clin Drug Investig       Date:  2019-12       Impact factor: 2.859

2.  Clinicoepidemiology of Skin Diseases in Children Seen at the University Hospital Center Morafeno, Toamasina, Madagascar.

Authors:  Irina Mamisoa Ranaivo; Fandresena Arilala Sendrasoa; Malalaniaina Andrianarison; Moril Sata; Onivola Raharolahy; Dimby Stephane Ralandison; Lala Soavina Ramarozatovo; Fahafahantsoa Rapelanoro Rabenja
Journal:  Dermatol Res Pract       Date:  2021-09-09

Review 3.  Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo.

Authors:  Yinghan Wang; Shuli Li; Chunying Li
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-20       Impact factor: 8.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.